Reduced circulating levels of TWEAK are associated with Gestational Diabetes Mellitus

European Journal of Clinical Investigation

Volumn 45, Issue 1, 2015, Pages 27-35

  Simón Muela, Inmaculada ^a,b,c   Llauradó, Gemma ^a,b,c   Chacón, Matilde Rodriguez ^c   Olona, Montserrat ^a   Näf, Silvia ^a,b,c   Maymó Masip, Elsa ^c   Gil, Pilar ^a,b,c   de la Flor, Miriam ^a   Gonzalez Clemente, Jose Miguel ^c,d   Vendrell, Joan ^a,b,c   Megía, Ana ^a,b,c  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL DE SABADELL   (Spain)

Author keywords

sTWEAK; Gestational diabetes mellitus; Insulin resistance; Low grade inflammation

Indexed keywords

CD163 ANTIGEN; CYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; BODY HEIGHT; BODY MASS; BODY WEIGHT; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLUCOSE METABOLISM; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MATERNAL BLOOD; METABOLIC PARAMETERS; MULTIPLE REGRESSION; NEWBORN; ORAL GLUCOSE TOLERANCE TEST; PONDERAL INDEX; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROGENY; PROSPECTIVE STUDY; THIRD TRIMESTER PREGNANCY; TRIACYLGLYCEROL BLOOD LEVEL; DEFICIENCY; DIABETES, GESTATIONAL; METABOLISM; PHYSIOLOGY; REGRESSION ANALYSIS;

ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CASE-CONTROL STUDIES; DIABETES, GESTATIONAL; FEMALE; HUMANS; INSULIN RESISTANCE; PREGNANCY; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; REGRESSION ANALYSIS; TUMOR NECROSIS FACTORS;

EID: 84921048168     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12375     Document Type: Article

References (34)

1. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 2007;30(Suppl. 2):S112-9.
2. Miehle K, Stepan H, Fasshauer M. Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. Clin Endocrinol (Oxf) 2012;76:2-11.
3. Lowe LP, Metzger BE, Lowe WL Jr, Dyer AR, McDade TW, McIntyre HD. Inflammatory mediators and glucose in pregnancy: results from a subset of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. J Clin Endocrinol Metab 2010;95:5427-34.
4. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007;40:1-16.
5. Feng F, Wang L, Albanese N, Holmes A, Xia P. Tumor necrosis factor-like weak inducer of apoptosis attenuates the action of insulin in hepatocytes. Endocrinology 2008;149:1505-13.
6. Vazquez-Carballo A, Ceperuelo-Mallafre V, Chacon MR, Maymo-Masip E, Lorenzo M, Porras A et al. TWEAK prevents TNF-alpha-induced insulin resistance through PP2A activation in human adipocytes. Am J Physiol Endocrinol Metab 2013;305:E101-12.
7. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Páramo JA, Michel JB et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:916-22.
8. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, Blüher M et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008;199:440-4.
9. Llaurado G, Gonzalez-Clemente JM, Maymo-Masip E, Subias D, Vendrell J, Chacon MR. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS ONE 2012;7:e43919.
10. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007;178:8183-94.
11. Moller HJ. Soluble CD163. Scand J Clin Lab Invest 2012;72:1-13.
12. Sporrer D, Weber M, Wanninger J, Weigert J, Neumeier M, Stögbauer F et al. Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity. Eur J Clin Invest 2009;39:671-9.
13. Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 2007;101:106-10.
14. Ricart W, Lopez J, Mozas J, Pericot A, Sancho MA, González N et al. Potential impact of American Diabetes Association (2000) criteria for diagnosis of gestational diabetes mellitus in Spain. Diabetologia 2005;48:1135-41.
15. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979;28:1039-57.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
18. Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, Sonmez A, Saglam M et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1716-23.
19. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL et al. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010;30:1253-62.
20. Martin-Ventura JL, Lindholt JS, Moreno JA, Vega de Céniga M, Meilhac O, Michel JB et al. Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 2011;214:486-9.
21. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010;211:322-6.
22. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:110-8.
23. Blanco-Colio LM, Martin-Ventura JL, Carrero JJ, Yilmaz MI, Moreno JA, Gómez-Guerrero C et al. Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. Proteomics Clin Appl 2011;5:281-8.
24. Diaz-Lopez A, Chacon MR, Bullo M, Maymó-Masip E, Martínez-González MA, Estruch R et al. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study. J Clin Endocrinol Metab 2013;98:3482-90.
25. Diaz-Lopez A, Bullo M, Chacon MR, Estruch R, Vendrell J, Díez-Espino J et al. Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk. Cardiovasc Diabetol 2014;13:51.
26. Akinci B, Celtik A, Genc S, Yener S, Demir T, Secil M et al. Evaluation of postpartum carbohydrate intolerance and cardiovascular risk factors in women with gestational diabetes. Gynecol Endocrinol 2011;27:361-7.
27. Retnakaran R. Glucose tolerance status in pregnancy: a window to the future risk of diabetes and cardiovascular disease in young women. Curr Diabetes Rev 2009;5:239-44.
28. Aristoteli LP, Moller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006;184:342-7.
29. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009;207:103-10.
30. Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf) 2012;77:385-90.
31. Paidas MJ, Ku DH, Davis B, Lockwood CJ, Arkel YS. Soluble monocyte cluster domain 163, a new global marker of anti-inflammatory response, is elevated in the first trimester of pregnancy. J Thromb Haemost 2004;2:1009-10.
32. Axelsson J, Moller HJ, Witasp A, Qureshi AR, Carrero JJ, Heimbürger O et al. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis 2006;48:916-25.
33. Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A. Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 2011;57:291-7.
34. Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM. Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Diabetes Care 2001;24:1602-7.